Leman Biotech Initiates Patient Recruitment for IIT Clinical Study of Meta10-19 Injection in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treatment
Leman Biotech has been granted approval from the First Affiliated Hospital of University of Science and Technology of China to conduct an Investigator-Initiated Trial (IIT) clinical study of Meta10-19 injection for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) (NCT05715606). The company has now announced the recruitment of patients for this study.